Advertisement

Qualigen Therapeutics, Inc. QLGN

Set alert

Price alert · QLGN

All alert types
3.21 0.00 0.00%

At close · Nov 18

2.86 Day range 3.34
3.34 52-week range 30.50
YTD
-23.75%
1 year
-11.81%
Open
2.98
Prev close
3.21
Mkt cap
2.98M
Vol
368.77K
Avg vol
92.24K
EPS
3,635.00
P/E
0.00
Div yield
0.00%
More statistics
Low
2.86
High
3.34
Forward P/E
-4.04
Beta
0.14
Short ratio
0.11
Inst. own
1.77%
Dividend
0.00
Ex-div date
Earnings
May 7, 2024
50-d avg
5.21
200-d avg
10.89
1y target
0.00

2Y chart

Chart tools
Interval

Events in this range
  • May 7, 2024Earnings: —; estimate -0.52; surprise —%
  • Jul 2, 2024Earnings: -17.5; estimate 0; surprise —%
  • Aug 14, 2024Earnings: -10; estimate 0; surprise —%
  • Nov 5, 2024Split: 1 for 50
  • Nov 14, 2024Earnings: -4.7; estimate 0; surprise —%
Signals (74)
NameDateAgo
MACD: Buy SignalNov 17, 202511 months ago
SMA: BearishOct 27, 20251 year ago
SMA: BearishOct 27, 20251 year ago
MACD: Sell SignalOct 8, 20251 year ago
RSI: OverboughtSep 29, 20251 year ago
RSI: OverboughtSep 25, 20251 year ago
SMA: BullishSep 22, 20251 year ago
SMA: BullishSep 18, 20251 year ago
RSI: OverboughtSep 18, 20251 year ago
RSI: OversoldSep 4, 20251 year ago
MACD: Buy SignalAug 18, 20251 year ago
RSI: OversoldJul 31, 20251 year ago
MACD: Sell SignalJul 18, 20251 year ago
SMA: BearishJul 17, 20251 year ago
SMA: BullishJul 16, 20251 year ago
SMA: BearishJul 15, 20251 year ago
SMA: BullishJul 14, 20251 year ago
MACD: Buy SignalJul 10, 20251 year ago
SMA: BullishJun 18, 20251 year ago
SMA: BearishJun 17, 20251 year ago
MACD: Sell SignalJun 6, 20251 year ago
MACD: Buy SignalJun 3, 20251 year ago
MACD: Sell SignalMay 23, 20251 year ago
SMA: BullishApr 21, 20251 year ago
SMA: BearishApr 17, 20251 year ago
MACD: Buy SignalApr 17, 20251 year ago
SMA: BullishApr 15, 20251 year ago
MACD: Sell SignalApr 7, 20251 year ago
SMA: BearishApr 3, 20251 year ago
SMA: BullishMar 27, 20251 year ago
MACD: Buy SignalMar 13, 20251 year ago
MACD: Sell SignalMar 10, 20251 year ago
MACD: Buy SignalMar 6, 20251 year ago
MACD: Sell SignalMar 3, 20251 year ago
MACD: Buy SignalFeb 13, 20251 year ago
MACD: Sell SignalJan 28, 20251 year ago
RSI: OversoldJan 28, 20251 year ago
SMA: BearishJan 27, 20251 year ago
SMA: BullishJan 23, 20251 year ago
SMA: BearishJan 7, 20251 year ago
MACD: Buy SignalNov 20, 20241 year ago
RSI: OversoldNov 11, 20241 year ago
RSI: OversoldOct 29, 20242 years ago
MACD: Sell SignalOct 24, 20242 years ago
RSI: OversoldOct 24, 20242 years ago
SMA: BearishOct 23, 20242 years ago
SMA: BullishOct 21, 20242 years ago
MACD: Buy SignalSep 16, 20242 years ago
MACD: Sell SignalAug 29, 20242 years ago
MACD: Buy SignalAug 22, 20242 years ago
SMA: BearishJul 26, 20242 years ago
SMA: BullishJul 25, 20242 years ago
MACD: Sell SignalJul 24, 20242 years ago
SMA: BullishJul 12, 20242 years ago
RSI: OverboughtJul 12, 20242 years ago
SMA: BearishJul 9, 20242 years ago
SMA: BullishJul 5, 20242 years ago
MACD: Buy SignalJun 27, 20242 years ago
RSI: OversoldJun 20, 20242 years ago
RSI: OversoldJun 17, 20242 years ago
RSI: OversoldJun 13, 20242 years ago
RSI: OversoldJun 6, 20242 years ago
MACD: Sell SignalJun 5, 20242 years ago
MACD: Buy SignalMay 1, 20242 years ago
RSI: OversoldApr 16, 20242 years ago
MACD: Sell SignalApr 12, 20242 years ago
MACD: Buy SignalMar 25, 20242 years ago
RSI: OversoldMar 19, 20242 years ago
MACD: Sell SignalMar 1, 20242 years ago
SMA: BearishFeb 27, 20242 years ago
SMA: BullishFeb 26, 20242 years ago
RSI: OversoldJan 11, 20242 years ago
RSI: OversoldJan 4, 20242 years ago
RSI: OversoldDec 15, 20232 years ago

Key statistics

Market cap
2.98M
Enterprise value
2.43M
Trailing P/E
0.00
Forward P/E
-4.04
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
3,635.00
Beta
0.14
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-4.66M
Total cash
118.69K
Total debt
1.67M
Return on equity
0.00%
Shares outstanding
736.43K
Short % of float
2.85%
50-day average
5.21
200-day average
10.89

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

May 7, 2024

Expected May 7, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
QLGN Revenue — quarterly 0
2022-Q2 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 2025
QLGN Net income — quarterly -1.69M
2022-Q2 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 2025
QLGN EPS — quarterly -1.00
2022-Q2 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 2025

Earnings

QLGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-4.70——
Aug 14, 2024Jun 1, 20240.00-10.00——
Jul 2, 2024Mar 1, 20240.00-17.50——
May 7, 2024Dec 1, 2023-0.52———
Nov 14, 2023Sep 1, 2023-46.00-32.00+14.00+30.43%
Aug 15, 2023Jun 1, 2023-26.00-34.50-8.50-32.69%

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
qlgntx.com

News

Your note

Sign in to keep a note on QLGN — it syncs with the Stock Master app.

Institution ownership

QLGN institution ownership
Holder% heldSharesValueReported
UBS Group AG0.56%4,09016.52KSep 29, 2024
Citadel Advisors Llc0.42%3,07212.41KSep 29, 2024
HRT Financial LP0.27%1,9567.90KSep 29, 2024
Geode Capital Management, LLC0.12%9153.70KSep 29, 2024
Blackrock Inc.0.07%5122.07KSep 29, 2024
Vanguard Group Inc0.06%4571.85KSep 29, 2024

Fund ownership

QLGN fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund4.86%35,761144.47KOct 30, 2024
Fidelity Series Total Market Index Fund0.40%2,92511.82KOct 30, 2024
Fidelity Total Market Index Fund0.21%1,5126.11KOct 30, 2024
Vanguard Extended Market Index Fund0.06%4571.85KSep 29, 2024
Advertisement